Skip to main content
SpringerLink
Log in

Optimising Thrombolytic Therapy in Elderly Patients with Acute Myocardial Infarction

  • Review Article
  • Drug Therapy
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The incidence of myocardial infarction (MI) and its subsequent mortality increases with age. However, elderly patients are less likely to receive thrombolytic therapy. Among other reasons, this may be because elderly patients with evolving MI often have atypical signs and symptoms and delay their presentation for medical treatment by 2 hours compared with younger patients.

The risk of (most often fatal) cerebral bleeding in elderly patients treated with aspirin, heparin and thrombolytic drugs is about 1 to 2 per 1000 patients, and is 2 times higher than in younger patients. In order to decrease the incidence of intracranial haemorrhage in elderly patients with acute MI, thrombolytic treatment should not be recommended in patients at increased risk of cerebral bleeding.

Otherwise, the benefit of thrombolytic treatment outweighs the risk; for every 1000 elderly patients treated with thrombolytic drugs, approximately 36 are saved compared with those receiving control treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Weaver WD, Litnin PE, Martin JS, et al. The MITI Project Group. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. J Am Coll Cardiol 1991; 18: 675–762

    Article  Google Scholar 

  2. Pfeiffer MA, Moyé LA, Braunwald E, et al. Selection bias in the use of thrombolytic therapy in acute myocardial infarction. JAMA 1991; 266: 528–32

    Article  Google Scholar 

  3. Sherry S, Marder V. Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderly. J Am Coll Cardiol 1991; 17: 1237–8

    Article  PubMed  CAS  Google Scholar 

  4. Yang XS, Willems JL, Pardaens J, et al. Acute myocardial infarction in the very elderly: a comparison with younger age groups. Acta Cardiol 1987; 42: 59–68

    PubMed  CAS  Google Scholar 

  5. Gurwitz JH, Goldberg RJ, Gore JM. Coronary thrombolysis for the elderly? JAMA 1991; 265: 1720–3

    Article  PubMed  CAS  Google Scholar 

  6. Montague TJ, Ikuta RM, Wong RY, et al. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987–1989). Am J Cardiol 1991; 68: 843–7

    Article  PubMed  CAS  Google Scholar 

  7. Sleight P. Is there an age limit for thrombolytic therapy? Am J Cardiol 1993; 72: 30G–33G

    Article  PubMed  CAS  Google Scholar 

  8. Ketley D, Woods KL. Age limits the use of thrombolytic drugs for acute myocardial infarction in most European countries [abstract]. Eur Heart J 1995; 16: 10

    Google Scholar 

  9. GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673–82

    Article  Google Scholar 

  10. Katz A, Cohn G, Mashal A, et al. Thrombolytic therapy for acute myocardial infarction in a 110-year old man. Am J Cardiol 1993; 71: 1122–3

    Article  PubMed  CAS  Google Scholar 

  11. Gruppo Italiano per lo Studio della Streptochinasi nell’ Infarcto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986 Feb 22; 1(8478): 397–401

    Google Scholar 

  12. ISIS-2 (Second International Study of Infarct Survival Collaborative Group). Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988 Aug 13; 2(8607): 349–60

    Google Scholar 

  13. Battershill PE, Benfield P, Goa KL. Streptokinase: a review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients. Drugs Aging 1994; 4(1): 63–86

    Article  PubMed  CAS  Google Scholar 

  14. Fibrinolysis Therapy Trialists (FFT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity, results from all randomized trials of more than 1,000 patients. Lancet 1994; 343: 311–21

    Google Scholar 

  15. Mauri F, de Brase M, Franzosi MG, et al. In hospital causes of death in the patients admitted to the GISSI study. G Ital Cardiol 1987; 17: 37–44

    PubMed  CAS  Google Scholar 

  16. Becker RC, Charlesworth A, Wilcox RG, et al. Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) study. J Am Coll Cardiol 1995; 25: 1063–8

    Article  PubMed  CAS  Google Scholar 

  17. Collins R. Optimizing thrombolytic therapy of acute myocardial infarction: age is not a contraindication [abstract]. Circulation 1991; 84: 11230

    Google Scholar 

  18. De Jaegere PP, Arnold AA, Balk AH, et al. Intracranial hemorrhage in association with thrombolytic therapy: incidence and clinical predictive factors. J Am Coll Cardiol 1992; 19: 289–94

    Article  PubMed  Google Scholar 

  19. Simoons ML, Maggioni AP, Knatterud GP, et al. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy. Lancet 1993; 342: 1523–8

    Article  PubMed  CAS  Google Scholar 

  20. Gore JM, Sloan M, Price TR, et al. Intracerebral hemorrage. Cerebral infarction and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the TIMI II pilot and clinical trial. Circulation 1991; 83: 448–59

    Article  PubMed  CAS  Google Scholar 

  21. Kase CS, O’Neal AM, Fisher M, et al. Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. Ann Intern Med 1990; 112: 17–21

    PubMed  CAS  Google Scholar 

  22. O’Connor CM, Califf RM, Massey EW, et al. Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long term prognosis. J Am Coll Cardiol 1990; 16: 553–60

    Article  Google Scholar 

  23. Mooradd M, Goldberg RJ, Gore JM. Thrombolytic therapy in the elderly patients. In: Becker RC, editor. The modern era of coronary thrombolysis. Boston: Kluwer Academic Publishers, 1994: 163–74

    Chapter  Google Scholar 

  24. AIMS trial study group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988; 1: 545–9

    Google Scholar 

  25. Wilcox RG, von der Lippe G, Olsson G, et al. Effects of alteplase in acute myocardial infarction: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombosis. Lancet 1990 May 19; 335: 1175–8

    PubMed  CAS  Google Scholar 

  26. Feit F, Breed J, Anderson JL, et al. A randomized, placebo-controlled, trial of tissue plasminogen activator in elderly patients with acute myocardial infarction [abstract]. Circulation 1990; 82 Suppl.: III–666

    Google Scholar 

  27. White H, Cross D, Scott M, et al. Comparison of effects of thrombolytic therapy on left ventricular function in patients over with those under 60 years of age. Am J Cardiol 1991; 67: 913–8

    Article  PubMed  CAS  Google Scholar 

  28. LATE study group. Late assessment of thrombolytic efficacy (LATE) study with alteplase in 6–24 hours after onset of acute myocardial infarction. Lancet 1993; 342: 759–66

    Article  Google Scholar 

  29. Chaitman BR, Thompson B, Wittry MD, et al. The use of tissue-type plasminogen activator for acute myocardial infarction in the elderly: results from thrombolysis in myocardial infarction Phase I, open label studies and the Thrombolysis in Myocardial Infarction Phase II pilot study. J Am Coll Cardiol 1989; 14: 1159–65

    Article  PubMed  CAS  Google Scholar 

  30. Anderson JL, Karagounis L, Allen A, et al. Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991; 68: 166–70

    Article  PubMed  CAS  Google Scholar 

  31. Tabone X, Vacheron A. La thrombolyse après 75 ans; bénéfices, risques, indications [in French]. Arch Mal Coeur Vaiss 1995; 88: 255–60

    PubMed  CAS  Google Scholar 

  32. Califf RM, Topol EJ, George BS, et al. Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. Am J Med 1988; 85: 353–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg O&N, Herestraat 49, B-3000, Leuven, Belgium

    Marc Verstraete & Desiré Collen

Authors
  1. Marc Verstraete
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Desiré Collen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Verstraete, M., Collen, D. Optimising Thrombolytic Therapy in Elderly Patients with Acute Myocardial Infarction. Drugs & Aging 8, 17–22 (1996). https://doi.org/10.2165/00002512-199608010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199608010-00004

Keywords

Search

Navigation